Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CYRX 
Cryoport Inc (CYRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CYRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $12.11
1 Year Target Price $12.11
| 4 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.5% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 432.58M USD | Price to earnings Ratio - | 1Y Target Price 12.11 |
Price to earnings Ratio - | 1Y Target Price 12.11 | ||
Volume (30-day avg) 10 | Beta 1.63 | 52 Weeks Range 4.58 - 10.46 | Updated Date 09/14/2025 |
52 Weeks Range 4.58 - 10.46 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 31.67% | Operating Margin (TTM) -21.23% |
Management Effectiveness
Return on Assets (TTM) -4.21% | Return on Equity (TTM) -9.19% |
Valuation
Trailing PE - | Forward PE 58.14 | Enterprise Value 273401603 | Price to Sales(TTM) 1.82 |
Enterprise Value 273401603 | Price to Sales(TTM) 1.82 | ||
Enterprise Value to Revenue 1.15 | Enterprise Value to EBITDA -13 | Shares Outstanding 50067000 | Shares Floating 43463135 |
Shares Outstanding 50067000 | Shares Floating 43463135 | ||
Percent Insiders 3.87 | Percent Institutions 100.71 |
Upturn AI SWOT
Cryoport Inc
Company Overview
History and Background
Cryoport Inc. was founded in 1998. Initially focused on cryogenic solutions for animal breeding, it evolved to become a leading provider of temperature-controlled supply chain solutions for the life sciences industry, especially the cell and gene therapy market. Significant milestones include strategic acquisitions and expansion into new geographic regions and service offerings.
Core Business Areas
- Cryoport Systems: Provides cryogenic shipping solutions, including containers, information systems (Cryoportal), and related services for the biopharma and life sciences industry.
- Cryoport Solutions: Offers temperature-controlled logistics services, including transportation, storage, and biostorage services for biological materials.
- MVE Biological Solutions: Manufactures cryogenic freezers and related equipment used for the storage and preservation of biological materials.
Leadership and Structure
Cryoport Inc. is led by CEO Jerrell Shelton. The company has a typical corporate structure with departments for operations, sales, marketing, finance, and research and development.
Top Products and Market Share
Key Offerings
- Cryoport Express Shippers: Proprietary cryogenic shipping containers used to transport temperature-sensitive biological materials. Cryoport estimates it supports a significant portion of commercial and clinical cell and gene therapy shipments globally. Competitors include World Courier, Marken (UPS Healthcare), and FedEx Custom Critical.
- Cryoportal: A logistics management platform that tracks shipments and provides real-time data. Revenue generated indirectly as it supports Cryoport's core shipping services. Competitors include bespoke tracking solutions from other logistics providers.
- Cryogenic Freezers (from MVE Biological Solutions): Cryogenic freezers and storage solutions. MVE Biological Solutions has a considerable market share in the cryopreservation freezer space, particularly for biostorage applications. Competitors include Thermo Fisher Scientific, Chart Industries, and Taylor-Wharton.
Market Dynamics
Industry Overview
The life sciences logistics industry is experiencing rapid growth, driven by the increasing demand for cell and gene therapies, personalized medicine, and clinical trials. The market is characterized by stringent regulatory requirements and a need for specialized temperature-controlled solutions.
Positioning
Cryoport Inc. is a leading player in the temperature-controlled supply chain solutions market for the life sciences industry, with a strong focus on the cell and gene therapy sector. Its competitive advantages include its proprietary technology, global network, and deep industry expertise.
Total Addressable Market (TAM)
The overall market for biopharma logistics is estimated to be in the billions of dollars, with the temperature-controlled segment representing a significant portion. Cryoport is positioned to capture an increasing share of this market through continued expansion and innovation.
Upturn SWOT Analysis
Strengths
- Specialized expertise in cryogenic logistics
- Proprietary technology and equipment
- Global network and infrastructure
- Strong relationships with leading biopharma companies
- High barrier to entry due to regulatory requirements
Weaknesses
- High reliance on the cell and gene therapy market
- Potential vulnerability to disruptions in the global supply chain
- Relatively high cost of services
- Customer concentration
Opportunities
- Expanding into new geographic markets
- Developing new products and services
- Acquiring complementary businesses
- Increased adoption of cell and gene therapies
- Growing demand for personalized medicine
Threats
- Competition from larger logistics companies
- Technological advancements that could disrupt the industry
- Changes in regulatory requirements
- Economic downturns
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- UPS
- FXDX
- THRM
Competitive Landscape
Cryoport's advantages include its specialization in cryogenic logistics and its focus on the cell and gene therapy market. Disadvantages include its smaller size compared to larger logistics companies like UPS and FedEx, potentially facing competition on pricing.
Major Acquisitions
MVE Biological Solutions
- Year: 2020
- Acquisition Price (USD millions): 320
- Strategic Rationale: Expanded Cryoport's product offerings to include cryogenic freezers and storage solutions, creating a more comprehensive solution for customers.
CryoPDP
- Year: 2020
- Acquisition Price (USD millions): 55
- Strategic Rationale: Expanded Cryoport's global footprint and capabilities in temperature-controlled logistics.
Growth Trajectory and Initiatives
Historical Growth: Cryoport has experienced significant growth in recent years, driven by the expansion of the cell and gene therapy market. This growth is reflected in their increasing revenue and market share.
Future Projections: Analyst estimates project continued growth for Cryoport, driven by the ongoing demand for temperature-controlled logistics solutions in the life sciences industry. Specific growth rates and revenue targets vary depending on the analyst.
Recent Initiatives: Recent initiatives include acquisitions to expand service offerings (e.g., biostorage) and investments in infrastructure to support future growth. Cryoport has invested in building more facilities across the globe and creating more streamlined processes.
Summary
Cryoport is a leading provider of temperature-controlled supply chain solutions for the life sciences industry with specialization in the cell and gene therapy market. Their growth is strongly tied to the expansion of the market and strategic acquisition and investment in infrastructure. Cryoport needs to be aware of larger logistics companies, potential regulations, and technology advancements in the industry. Overall, Cyroport is in a strong position for growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cryoport Inc. Investor Relations
- Company Filings (SEC)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cryoport Inc
Exchange NASDAQ | Headquaters Brentwood, TN, United States | ||
IPO Launch date 2005-03-15 | Chairman, President & CEO Mr. Jerrell W. Shelton | ||
Sector Industrials | Industry Integrated Freight & Logistics | Full time employees 1090 | Website https://www.cryoportinc.com |
Full time employees 1090 | Website https://www.cryoportinc.com | ||
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.